The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on Neurizon Therapeutics Limited’s investigational therapy, NUZ-001, a significant step forward for the company’s efforts in treating Amyotrophic Lateral Sclerosis (ALS). This decision allows Neurizon to proceed with the drug’s development within the HEALEY ALS Platform Trial, which is anticipated to begin in the fourth quarter of 2025.
Dr. Michael Thurn, Managing Director and CEO of Neurizon, expressed optimism about the FDA’s decision. “The FDA’s clearance of our IND application marks a significant milestone in our mission to bring NUZ-001 closer to patients living with ALS,” he stated. Thurn emphasized the company’s commitment to rigorous scientific development and acknowledged the crucial support from key opinion leaders and patient advocacy groups in advancing this program.
The lifting of the clinical hold is underpinned by comprehensive preclinical safety data and detailed manufacturing information obtained through Neurizon’s licensing agreement with Elanco. This robust foundation supports the potential of NUZ-001 as a platform molecule, paving the way for future expansions into additional therapeutic indications.
Next Steps in ALS Treatment Development
With the IND now active, Neurizon is poised to collaborate with Mass General Hospital (MGH) in filing a protocol amendment for the HEALEY ALS Platform Trial. This amendment will incorporate a specific regimen for NUZ-001, with patient enrollment expected to commence in late 2025.
Neurizon’s strategic focus aims to accelerate patient access to innovative therapies, highlighting its intent to establish NUZ-001 as a viable treatment option for ALS. The company believes that the drug has the potential to slow the progression of this challenging disease significantly, as evidenced by encouraging survival outcomes from earlier studies.
The regulatory foundation provided by the IND not only expedites the development of NUZ-001 but also streamlines the processes for future therapeutic programs. By establishing a validated framework for safety and clinical design, Neurizon aims to reduce regulatory risks and enhance its capacity to address broader neurodegenerative conditions.
Neurizon Therapeutics Limited is committed to transforming the landscape of ALS treatment, focusing on both immediate patient needs and long-term shareholder value. As the company moves forward with its clinical trials, it remains dedicated to creating innovative solutions for those affected by neurodegenerative diseases.
This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction. Neurizon® is a registered trademark of Neurizon Therapeutics Limited.
